Literature DB >> 24598720

Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.

C Keijzer1, B J Haijema2, T Meijerhof3, P Voorn2, A de Haan3, K Leenhouts4, M L van Roosmalen2, W van Eden1, F Broere1.   

Abstract

BACKGROUND: Nasal vaccination is considered to be a promising alternative for parenteral vaccination against influenza virus as it is non-invasive and offers the opportunity to elicit strong antigen-specific responses both systemic and locally at the port of entry of the pathogen. Previous studies showed that non-living bacterium-like particles (BLPs) from the food-grade bacterium Lactococcus lactis are effective stimulators of local and systemic immune responses when administered intranasally. Moreover, in vitro, BLPs specifically interact with human Toll-like receptor 2 (TLR2), suggestive of a role for TLR2 dependent immune activation by BLPs.
METHODS: In the present study, we examined the role of TLR2 in vivo in immune activation after nasal administration of BLP mixed with split influenza vaccine (BLP-SV) of influenza A virus (IAV) using TLR2 knockout mice.
RESULTS: The systemic Th1 cell and subsequent B-cell responses induced after intranasal BLP-SV vaccination depended on the interaction of BLPs with TLR2. Notably, the BLP-SV-induced class switch to IgG2c depended on the interaction of BLP with TLR2. Local induced IAV-specific Th1 cell responses and the mucosal B-cell responses also depended on interaction of BLP with TLR2. Strongly reduced SIgA levels were observed in TLR2 knockout mice both in the nasal and vaginal lavages. In addition, detailed analysis of the T-cell response revealed that nasal BLP-SV vaccination promoted Th1/Th17 immune responses that coincided with increased IAV-specific IgG2c antibody production. DISCUSSION: Altogether these results indicate that nasal BLP-SV vaccination induces IAV-specific T-cell and B-cell responses, both systemically and at the site of virus entry in a TLR2-dependent manner.
Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Bacterium-like particles (BLP); Humoral immunity; Influenza A virus; Nasal vaccination; T-cell responses; Toll-like receptor 2 (TLR2)

Mesh:

Substances:

Year:  2014        PMID: 24598720     DOI: 10.1016/j.vaccine.2014.02.019

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

Review 1.  Current prospects and future challenges for nasal vaccine delivery.

Authors:  Helmy Yusuf; Vicky Kett
Journal:  Hum Vaccin Immunother       Date:  2016-12-09       Impact factor: 3.452

2.  Comparative studies of infectivity, immunogenicity and cross-protective efficacy of live attenuated influenza vaccines containing nucleoprotein from cold-adapted or wild-type influenza virus in a mouse model.

Authors:  Irina Isakova-Sivak; Daniil Korenkov; Tatiana Smolonogina; Tatiana Tretiak; Svetlana Donina; Andrey Rekstin; Anatoly Naykhin; Svetlana Shcherbik; Nicholas Pearce; Li-Mei Chen; Tatiana Bousse; Larisa Rudenko
Journal:  Virology       Date:  2016-11-06       Impact factor: 3.616

3.  Biophysical characterization of the type III secretion tip proteins and the tip proteins attached to bacterium-like particles.

Authors:  Shyamal P Choudhari; Xiaotong Chen; Jae Hyun Kim; Maarten L Van Roosmalen; Jamie C Greenwood; Sangeeta B Joshi; William D Picking; Kees Leenhouts; C Russell Middaugh; Wendy L Picking
Journal:  J Pharm Sci       Date:  2014-06-10       Impact factor: 3.534

4.  The expression of B & T cell activation markers in children's tonsils following live attenuated influenza vaccine.

Authors:  Jack A Panapasa; Rebecca J Cox; Kristin G I Mohn; Lara A Aqrawi; Karl A Brokstad
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Shigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice.

Authors:  Shannon J Heine; Olga L Franco-Mahecha; Xiaotong Chen; Shyamal Choudhari; William C Blackwelder; Maarten L van Roosmalen; Kees Leenhouts; Wendy L Picking; Marcela F Pasetti
Journal:  Immunol Cell Biol       Date:  2015-03-17       Impact factor: 5.126

6.  Passive inhalation of dry powder influenza vaccine formulations completely protects chickens against H5N1 lethal viral challenge.

Authors:  Jasmine Tomar; Carin Biel; Cornelis A M de Haan; Peter J M Rottier; Nikolai Petrovsky; Henderik W Frijlink; Anke Huckriede; Wouter L J Hinrichs; Ben Peeters
Journal:  Eur J Pharm Biopharm       Date:  2018-10-09       Impact factor: 5.571

7.  Rotavirus VP6 protein mucosally delivered by cell wall-derived particles from Lactococcus lactis induces protection against infection in a murine model.

Authors:  C Facundo Temprana; Marcelo H Argüelles; Nicolás M Gutierrez; Patricia A Barril; Laura E Esteban; Dalila Silvestre; Marcelo G Mandile; Graciela Glikmann; Alejandro A Castello
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

8.  Inflammatory responses to infection: the Dutch contribution.

Authors:  Martijn A Nolte; Jos W M van der Meer
Journal:  Immunol Lett       Date:  2014-10-18       Impact factor: 3.685

9.  RNA is an Adjuvanticity Mediator for the Lipid-Based Mucosal Adjuvant, Endocine.

Authors:  Masayuki Hayashi; Taiki Aoshi; Koji Ozasa; Takato Kusakabe; Masatoshi Momota; Yasunari Haseda; Shingo Kobari; Etsushi Kuroda; Kouji Kobiyama; Cevayir Coban; Ken J Ishii
Journal:  Sci Rep       Date:  2016-07-04       Impact factor: 4.379

Review 10.  Innovative Mucosal Vaccine Formulations Against Influenza A Virus Infections.

Authors:  Cynthia Calzas; Christophe Chevalier
Journal:  Front Immunol       Date:  2019-07-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.